I-3344 INK128, Free Base, >99%

Synonyms : [MLN0128] [Sapanisertib]

  • Size
  • US $
  • €
  • £
  • ¥
  • 25 mg
  • 155
  • 144
  • 124
  • 21,700
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 236
  • 220
  • 189
  • 33,000
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 418
  • 389
  • 335
  • 58,400
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 633
  • 590
  • 508
  • 88,500
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 864
  • 806
  • 693
  • 120,800
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 1,245
  • 1,161
  • 999
  • 174,100
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 1,930
  • 1,800
  • 1,549
  • 269,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
Compare Quality and Prices — LC Labs vs. Other Suppliers
  • M.W. 309.33
  • C15H15N7O
  • [1224844-38-5]

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • INK128 is a potent mTOR kinase inhibitor with a Ki of 1.4 nM. It had therapeutic benefit for prostate cancer metastasis. Hsieh A.C., et al. "The translational landscape of mTOR signalling steers cancer initiation and metastasis." Nature 485: 55-61 (2012).
  • INK128 potently blocked cell proliferation in various breast cancer cell lines harboring PIK3CA (IC50 = 1.5-53 nM), PTEN (IC50 = 1-149 nM), KRAS and/or BRAF mutations (IC50 = 13-162 nM), and in human endothelial cells (IC50 = 33-40 nM) in vitro. In vivo, INK128 suppressed primary tumor growth significantly in both non-VEGF and VEGF-driven MCF-7 xenograft models. Gökmen-Polar Y., et al. "Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models." Breast Cancer Res. Treat. 136: 673-682 (2012).
  • INK128 inhibited proliferation of B-cell acute lymphoblastic leukemia (B-ALL) cell lines in vitro and suppressed colony formation by primary human leukemia cells from adult and pediatric B-ALL patients. INK128 enhanced the efficacy of dasatinib in Philadelphia Chromosome-positive (Ph+) specimens. In a syngeneic mouse model of lymphoid BCR-ABL+ disease, INK128 rapidly cleared leukemic outgrowth. In non-Ph+, B-ALL xenografts, INK128 had a cytostatic effect. Janes M.R., et al. "Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia." Leukemia 27: 586-594 (2013).
  • The addition of lapatinib to INK-128 treatment resulted in inhibition of both PI3K/Akt/mTOR and ERK pathways and prevented both HER2 and HER3 phosphorylation induced by INK-128. This dual blockade demonstrated antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. García-García C., et al. "Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy." Clin. Cancer Res. 18: 2603-2612 (2012).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • Not available in some countries; not available to some institutions; not available for some uses.
554